Biotech's renaissance: when scientific discovery starts paying off

For much of the past three years, biotechnology was one of the market's forgotten sectors. Investors gravitated toward large technology companies and other areas of the market that appeared to offer clearer growth prospects, while many biotech companies struggled despite continued advances in medical research.

That appears to be changing.

Biotechnology has been one of the stronger-performing sectors in 2026, supported by improving investor sentiment, increased merger activity, and, most importantly, a wave of promising scientific breakthroughs. While the sector remains volatile and highly specialized, there are signs that investors are once again rewarding innovation and medical progress.

Part of the recovery stems from valuation. After several years of underperformance, healthcare and biotechnology companies entered 2026 trading at significant discounts to the broader market. Investors had become focused on regulatory concerns, drug pricing debates, and rising interest rates. As some of those fears subsided, attention shifted back to what ultimately matters most in this industry: the ability to develop new therapies that improve patient outcomes.

The pace of discovery has been remarkable.

One of the most closely watched developments this year has been the emergence of personalized cancer vaccines. Moderna and Merck recently reported encouraging results from a treatment designed specifically around an individual patient's tumour characteristics. While still in the early stages, the results suggest medicine may be moving toward a future where therapies can be customized to the biology of each patient rather than relying solely on one-size-fits-all treatments.

Another notable breakthrough came from Revolution Medicines, which recently received approval for a new treatment targeting pancreatic cancer, one of the most difficult cancers to treat successfully. Advances in diseases that have historically seen few therapeutic improvements tend to attract significant attention from both physicians and investors, and for good reason. The greatest opportunities often emerge where medical needs remain largely unmet.

Large pharmaceutical companies are taking notice. Many industry leaders face patent expirations on blockbuster drugs over the coming decade and need new products to replace those revenues. Rather than relying exclusively on internal research programs, they are increasingly partnering with or acquiring innovative biotechnology companies.

This creates a virtuous cycle. Smaller biotechnology firms focus on discovery and development, while larger pharmaceutical companies provide the capital, manufacturing capabilities, and global distribution networks needed to bring successful therapies to patients. The result is an ecosystem that rewards breakthrough science and helps move promising treatments from the laboratory into widespread clinical use.

Of course, biotechnology remains a challenging area for investors. Clinical trials fail. Regulatory approvals can be delayed. Even promising discoveries do not always translate into commercial success. Progress rarely occurs in a straight line.

Yet the long-term backdrop remains compelling. Populations are aging across much of the developed world. Demand for better treatments continues to grow. Advances in oncology, genetics, rare diseases, and immunology are creating opportunities that simply did not exist a decade ago.

What stands out today is that the industry's momentum appears to be driven less by speculation and more by tangible progress. Investors are becoming excited not because of a market narrative, but because companies are producing therapies that have the potential to meaningfully change lives.

Markets often move in cycles of excitement and disappointment. Biotechnology has certainly experienced both over the past decade. But after several difficult years, the sector appears to be entering a period where scientific discovery is once again taking center stage.

Fraser Betkowski

The opinions expressed in this report are the opinions of the author and readers should not assume they reflect the opinions or recommendations of Richardson Wealth Limited or its affiliates. Richardson Wealth Limited is a subsidiary of iA Financial Corporation Inc. and is not affiliated with James Richardson & Sons, Limited. Richardson Wealth is a trade-mark of James Richardson & Sons, Limited and Richardson Wealth Limited is a licensed user of the mark. Richardson Wealth Limited, Member Canadian Investor Protection Fund.